Hikal Limited

rs,

change Plaza, Bandra-Kurla Complex, Bandra, Mumbai - 400 051. Symbol: HIKAL BSE Ltd., P J Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 524735 Dear Sir/Madam, Subject: Results Presentati

Rs 1860

an’s Message Jai Hiremath Executive Chairman “For the financial year 2025, we achieved revenue of Rs 1860 Cr, and EBITDA stood at Rs 328 Cr with EBITDA margin of 17.7%. In FY25, we delivered positive financ

Rs 328

tive Chairman “For the financial year 2025, we achieved revenue of Rs 1860 Cr, and EBITDA stood at Rs 328 Cr with EBITDA margin of 17.7%. In FY25, we delivered positive financial performance. Our results re

17.7%

l year 2025, we achieved revenue of Rs 1860 Cr, and EBITDA stood at Rs 328 Cr with EBITDA margin of 17.7%. In FY25, we delivered positive financial performance. Our results reflect a clear alignment to pos

Rs 0.80

g opportunities across both businesses. Our Board of Directors has recommended a final dividend of Rs 0.80 per share (40%). Along with an interim dividend of Rs. 0.60 per share (30%) declared in February 202

40%

oss both businesses. Our Board of Directors has recommended a final dividend of Rs 0.80 per share (40%). Along with an interim dividend of Rs. 0.60 per share (30%) declared in February 2025, the total d

Rs. 0.60

tors has recommended a final dividend of Rs 0.80 per share (40%). Along with an interim dividend of Rs. 0.60 per share (30%) declared in February 2025, the total dividend for FY25 stands at Rs 1.40 per share (

30%

a final dividend of Rs 0.80 per share (40%). Along with an interim dividend of Rs. 0.60 per share (30%) declared in February 2025, the total dividend for FY25 stands at Rs 1.40 per share (70% of FV). T

Rs 1.40

vidend of Rs. 0.60 per share (30%) declared in February 2025, the total dividend for FY25 stands at Rs 1.40 per share (70% of FV). The company’s balance sheet has further strengthened. Our Net Debt/Equity ha

70%

per share (30%) declared in February 2025, the total dividend for FY25 stands at Rs 1.40 per share (70% of FV). The company’s balance sheet has further strengthened. Our Net Debt/Equity has improved fro

Rs 552

iture largely from internal accruals. In Q4 FY25, at an overall company level, our revenue stood at Rs 552 Cr. with an EBITDA margin of 22.4%. In Q4 FY25, our pharmaceutical business reported revenue growth

22.4%

. In Q4 FY25, at an overall company level, our revenue stood at Rs 552 Cr. with an EBITDA margin of 22.4%. In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 Cr and EBIT grow

Note

1

Company

1

Investor Relations Advisors

1

Note

Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Not all countries and territories labeled. 2222 Manufacturing Capabilities Pharmaceuticals Jigani Unit 1, Karnataka • US FDA Approved API and Advanced Intermediates Manufacturing Site Jigani Unit 2, Karnataka • Scale-up and Launch Plant • Multipurpose and Multi-product cGMP Facility – • cGMP Multipurpose API Facilities. APIs and Intermediates. Panoli, Gujarat • Acquired Manufacturing site from Novartis in 2000 • US FDA Approved Site for KSMs and APIs • Four Multipurpose facilities 615 m3 TOTAL REACTOR VOLUME 93 m3 TOTAL REACTOR VOLUME 737 m3 TOTAL REACTOR VOLUME Crop Protection Mahad, Maharashtra • First Manufacturing Facility of Hikal • Specialty Chemicals, Fungicides, Herbicides, and Taloja, Maharashtra • Commissioned in 1997 in Technical Collaboration with Innovator company Panoli, Gujarat • Acquired Manufacturing site from Novartis

Investor Relations Advisors

Strategic Growth Advisors Pvt. Ltd CIN: U74140MH2010PTC204285 Mr. Jigar Kavaiya / Ms. Ami Parekh +91-9920602034 / +91-8082466052 jigar.kavaiya@sgapl.net/ ami.parekh@sgapl.net www.hikal.com www.sgapl.net